Company intelligence / Profile preview

Beijing Inoxin Pharmaceutical Technology

Beijing, Beijing, China

Ownership: Private
Development stage: Other

Overview

Inoxin Pharma is a clinical-stage biotechnology company based in Beijing, China, specializing in the discovery and development of innovative small molecule therapeutics for metabolic and endocrine disorders. The company focuses on high-prevalence conditions such as type 2 diabetes, obesity, and nonalcoholic steatohepatitis (NASH/MASH). Their lead programs include oral small molecule agonists targeting the GLP-1 receptor, designed to provide more convenient alternatives to injectable biologics. Inoxin leverages its expertise in medicinal chemistry to optimize the pharmacological profiles of its candidates for improved efficacy and safety.

Therapeutic areas: EndocrinologyGastroenterologyMetabolic Disorders
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Beijing Inoxin Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Inoxin Pharmaceutical Technology.

Explore the full profile